Nektar Therapeutics has posted updated data on its NKTR-214-Opdivo cocktail in first-line melanoma. The data features four more complete responses, bringing the rate up 10 percentage points to 34%.
A long-time skeptic of Nektar Therapeutics on Wall Street remains cautious after Monday’s 42 percent plunge, the worst performance for an S&P 500 Index member in more than five years.